Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Johnson & Johnson, solvency ratios (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The solvency profile exhibits a period of increased leverage and a significant adjustment in interest coverage capacity between 2022 and 2026.

Debt-to-Equity and Debt-to-Capital Ratios
A synchronized trend is observed, characterized by a notable peak in April 2023, where the debt-to-equity ratio reached 0.75 and the debt-to-capital ratio reached 0.43. Following this peak, these ratios normalized before entering a phase of moderate fluctuation. The debt-to-equity ratio concluded the period at 0.58, while the debt-to-capital ratio ended at 0.37, indicating a higher reliance on debt compared to the start of the analyzed period.
Debt-to-Assets Ratio
The debt-to-assets ratio remained relatively stable, fluctuating within a narrow band between 0.18 and 0.27. Periodic peaks occurred in April 2023 and March 2025. The relative consistency of this ratio suggests that the overall debt burden has been maintained at a sustainable level relative to the total asset base.
Financial Leverage
Financial leverage remained consistently within a range of 2.33 to 2.77. The maximum value of 2.77 was reached in April 2023, correlating with the peaks in other debt ratios. The ratio concluded at 2.37, returning to levels similar to those seen in early 2022, reflecting a balanced long-term capital structure.
Interest Coverage Ratio
A significant contraction is observed in the interest coverage ratio, which declined from a high of 164.15 in April 2022 to a low of 19.09 in October 2023. Following this sharp decline, the ratio established a new baseline, fluctuating between 23.10 and 36.24 through 2026, and ending the period at 25.90. This indicates a substantial reduction in the earnings-to-interest buffer.

Debt Ratios


Coverage Ratios


Debt to Equity

Johnson & Johnson, debt to equity calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Loans and notes payable
Long-term debt, excluding current portion
Total debt
 
Total Johnson & Johnson shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Debt to equity = Total debt ÷ Total Johnson & Johnson shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The solvency profile is characterized by fluctuating leverage levels and a long-term expansion of the equity base. While the overall financial structure remains stable, periodic increases in borrowing have created volatility in the debt-to-equity ratio over the analyzed period.

Total Debt Trends
Total debt exhibits significant volatility, with two distinct peaks occurring in April 2023 ($52.91 billion) and March 2026 ($54.99 billion). A substantial deleveraging phase is observed in the latter half of 2023, with debt levels reaching a period low of $29.33 billion in December 2023 before trending upward again through 2024 and 2025.
Shareholders' Equity Evolution
Shareholders' equity demonstrates a general upward trajectory over the long term. After a period of fluctuation and a low point of $68.77 billion in December 2023, equity entered a sustained growth phase, increasing consistently to reach $84.97 billion by June 2026.
Debt to Equity Ratio Analysis
The debt-to-equity ratio reflects the combined impact of debt volatility and equity growth, oscillating between a low of 0.42 and a high of 0.75. A sharp increase in leverage is evident in early 2023, peaking at 0.75 in April. This was followed by a rapid correction back to 0.42 by October 2023. A second cycle of leverage expansion occurred between late 2023 and early 2026, where the ratio peaked at 0.68 in March 2026 before moderating to 0.58 by June 2026.

Debt to Capital

Johnson & Johnson, debt to capital calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Loans and notes payable
Long-term debt, excluding current portion
Total debt
Total Johnson & Johnson shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The analysis of solvency metrics reveals a period of volatility in debt levels and capital structure from early 2022 through mid-2026. While the debt-to-capital ratio remained relatively stable in the initial phase, subsequent quarters show distinct cycles of leverage expansion and contraction.

Debt to Capital Ratio Trends
The ratio began at 0.31 in April 2022, maintaining a baseline of approximately 0.30 for much of the year before increasing to 0.34 by December 2022. A significant peak occurred in April 2023, where the ratio reached 0.43, coinciding with a surge in total debt to 52,907 million. This was followed by a sharp correction, with the ratio returning to 0.30 by October and December 2023.
Long-term Solvency Patterns
From 2024 through mid-2026, the debt-to-capital ratio established a higher average range, typically fluctuating between 0.32 and 0.40. The ratio peaked at 0.40 in December 2024 and again in March 2026, suggesting a shift toward a more leveraged capital structure compared to the 2022 baseline.
Total Debt and Capital Correlation
Total capital expanded from 107,857 million in April 2022 to 134,007 million by June 2026. This growth was periodically accompanied by substantial increases in total debt, which reached a maximum of 54,987 million in March 2026. The correlation between the growth in total capital and the spikes in total debt indicates that capital expansion was frequently supported by increased borrowing.

Debt to Assets

Johnson & Johnson, debt to assets calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Loans and notes payable
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The solvency profile exhibits a cyclical pattern characterized by periodic increases in leverage followed by strategic reductions. The debt-to-assets ratio fluctuates within a range of 0.18 to 0.27 over the observed period, indicating a managed approach to debt financing despite significant shifts in total liabilities.

Debt-to-Asset Ratio Trends
The ratio demonstrates two primary peaks of 0.27, occurring in April 2023 and March 2025. These peaks are interspersed with periods of deleveraging, most notably in the latter half of 2023 when the ratio returned to a low of 0.18. From late 2024 through mid-2026, the ratio maintains a higher baseline, oscillating between 0.24 and 0.27, which indicates a slightly higher structural reliance on debt relative to assets compared to the 2022 baseline.
Total Debt Volatility
Total debt displays substantial quarterly variance. A significant increase is observed between December 2022 (39,659 million) and April 2023 (52,907 million). Similarly, a sharp rise occurs between December 2024 (36,634 million) and March 2025 (52,252 million). These spikes are typically followed by reductions, such as the decline to 29,332 million by December 2023, suggesting tactical borrowing or the scheduled repayment of obligations.
Total Asset Trajectory
The total asset base shows a general upward trend, growing from 178,355 million in April 2022 to 201,061 million by June 2026. A notable contraction occurred in October 2023, where assets fell to 166,061 million, coinciding with a period of reduced total debt. The subsequent recovery and expansion of the asset base provided a buffer that helped stabilize the solvency ratio as total debt levels rose again during 2025 and 2026.

Financial Leverage

Johnson & Johnson, financial leverage calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Total assets
Total Johnson & Johnson shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Financial leverage = Total assets ÷ Total Johnson & Johnson shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The overall financial position exhibits a long-term expansion of the balance sheet, characterized by a steady increase in both total assets and shareholders' equity from April 2022 through June 2026. While the period was marked by notable volatility during 2023, the company maintained a stable solvency profile with a managed approach to financial leverage.

Total Assets Evolution
Total assets grew from $178,355 million in April 2022 to $201,061 million by June 2026. A significant contraction occurred on October 1, 2023, when assets dropped to $166,061 million. This was followed by a consistent recovery and growth trend that persisted through the end of the analyzed period.
Shareholders' Equity Trends
Equity increased from $74,709 million to $84,971 million. A downward trend was observed through late 2023, with equity reaching a minimum of $68,774 million in December 2023. Subsequently, a period of sustained growth in equity began, contributing to a stronger capital base by 2026.
Financial Leverage Dynamics
The financial leverage ratio fluctuated between a low of 2.33 and a peak of 2.77. The peak in April 2023 indicates a temporary increase in the reliance on debt to finance assets. Following this spike, the ratio generally stabilized, trending downward toward 2.37 by June 2026. This trajectory suggests a strategic realignment toward a more conservative leverage position relative to the asset base.

Interest Coverage

Johnson & Johnson, interest coverage calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Net earnings (loss)
Less: Net earnings (loss) from discontinued operations, net of tax
Add: Income tax expense
Add: Interest expense, net of portion capitalized
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Amgen Inc.
Danaher Corp.
Gilead Sciences Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Interest coverage = (EBITQ2 2026 + EBITQ1 2026 + EBITQ4 2025 + EBITQ3 2025) ÷ (Interest expenseQ2 2026 + Interest expenseQ1 2026 + Interest expenseQ4 2025 + Interest expenseQ3 2025)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


A significant contraction in the interest coverage ratio is observed over the analyzed period, transitioning from an exceptionally high liquidity position in early 2022 to a more stabilized, lower baseline by 2026. The initial phase of the period is characterized by a precipitous decline in the ratio, which fell from 164.15 in April 2022 to 19.09 by October 2023, reflecting a reduction in the margin of safety for debt servicing.

Earnings Before Interest and Tax (EBIT) Volatility
Operating earnings exhibited substantial fluctuations, notably a sharp contraction to negative 1,075 million in April 2023. This was followed by a period of recovery and a significant peak of 13,835 million in March 2025. By 2026, EBIT stabilized within a range of 6,262 million to 7,028 million, providing a consistent foundation for interest obligations.
Interest Expense Escalation
There is a clear upward trend in net interest expenses. Costs rose from a minimum of 10 million in April 2022 to a peak of 308 million in June 2025. This escalation suggests an increase in the cost of borrowing or an expansion of the total debt load, which acted as a primary driver in the compression of the coverage ratio.
Interest Coverage Ratio Stabilization
Following the initial decline, the interest coverage ratio entered a stabilization phase starting in 2024. The ratio fluctuated between 23.10 and 36.24 throughout 2024 and 2025, eventually settling around 25.00 to 25.90 in the first half of 2026. While these levels are substantially lower than the 2022 peaks, they indicate a sustained capacity to meet interest payments from operating profits.

The overall solvency profile indicates a shift from an over-capitalized or low-debt state to a more leveraged position. The convergence of rising interest costs and fluctuating operating income initially strained the coverage capacity, but the subsequent stabilization of EBIT in 2025 and 2026 has mitigated the risk of insolvency, maintaining a coverage ratio well above the critical threshold of 1.0x.